|Mr. Philip Astley-Sparke||Exec. Chairman, Sec. & Treasurer||573.59k||N/A||1971|
|Dr. Robert Coffin||Pres, CEO & Director||716.99k||N/A||1965|
|Dr. Colin Love||Chief Operating Officer||419.37k||N/A||1958|
|Dr. Howard L. Kaufman F.A.C.S., M.D., M.B.A.||Chief Medical Officer||548.1k||N/A||1961|
|Stephen Gorgol||Chief Accounting Officer||N/A||N/A||1959|
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 8; Compensation: 8.